1 of 1
Story summary
- Citi analysts say petrelintide, developed by Roche Holding and Zealand Pharma, may perform better in combination with Roche's CT-388 than alone.
- A midstage trial showed petrelintide's efficacy was underwhelming and its tolerability resembled placebo.
- A late-stage monotherapy study is planned to begin in the second half of the year.
- A midstage trial for the combination therapy is planned as well.
